Dylan Bertoni

Thomas Jefferson University Hospital

Papers

1

Total Citations

24

H-Index

1

About

Dylan Bertoni is a rising clinical researcher whose work focuses on optimizing treatment strategies for head and neck cancers, particularly oropharyngeal squamous cell carcinoma (OPSCC). His most cited study, published in 2023, addresses a critical gap in oncologic decision-making by comparing functional and survival outcomes between patients receiving primary transoral robotic surgery (TORS) versus primary chemoradiation therapy for early-stage (T1-T2) OPSCC. With 24 citations in a short time, this work has already informed ongoing debates about the trade-offs between surgical and non-surgical approaches, especially given the absence of high-powered randomized trials. Bertoni’s research is notable for its emphasis on patient-centered outcomes, including swallowing function and quality of life, alongside traditional survival metrics. His contributions are particularly relevant in the era of HPV-related OPSCC, where treatment de-escalation is a key priority. By providing real-world evidence to guide multidisciplinary care, Bertoni is helping to shape more personalized, less morbid treatment paradigms for patients facing this increasingly common cancer.

Research Focus

Key Achievements

1
H-Index
1
Papers
24
Total Citations
24
Avg Citations/Paper
🏆 Most Cited Paper
Differences in Functional and Survival Outcomes Between Patients Receiving Primary Surgery vs Chemoradiation Therapy for Treatment of T1-T2 Oropharyngeal Squamous Cell Carcinoma
24 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: Thomas Jefferson University Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago